Study drug XP-102 with trametinib for BRAF-mutated advanced cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This Phase 1/2 trial tests XP-102 alone and combined with trametinib in adults with advanced cancers that have a BRAF V600 mutation. It aims to see how well these treatments can control the cancer and how safe they are for people whose standard treatments didn’t work or aren’t available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is an advanced solid tumor with a BRAF V600 mutation (melanoma, colorectal cancer, non-small cell lung cancer, or thyroid cancer).
- Your cancer has either gotten worse after standard treatment, or standard treatment isn’t available or you can’t have it.
- You have at least one measurable tumor spot for monitoring; if brain metastases are present, they cannot be the only measurable ones.
- Your body function checks are adequate (liver, kidneys, blood clotting, heart, and blood counts), and your overall ability to do daily activities is ECOG 0–1.
- You can safely take the study drugs (no serious active infections; not allergic to XP-102 or trametinib; and your pregnancy test and birth-control plans are in place if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This trial tests two new drugs, HX009 and IN10018, with or without standard chemotherapy, for people with advanced solid tumors that haven't responded to treatment or have no standard options. It aims to see if this combination can help shrink or control the cancer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.